Report cover image

Adrenal Crisis Management Market Forecasts to 2032 – Global Analysis By Treatment Type (Glucocorticoid Therapy, Mineralocorticoid Therapy, Fluid & Electrolyte Replacement Therapy and Adjunctive Therapies), Route of Administration (Intravenous, Intramuscul

Publisher Stratistics Market Research Consulting
Published Sep 02, 2025
Length 200 Pages
SKU # SMR20346653

Description

According to Stratistics MRC, the Global Adrenal Crisis Management Market is accounted for $2.6 billion in 2025 and is expected to reach $4.4 billion by 2032 growing at a CAGR of 7.5% during the forecast period. Adrenal crisis management involves the immediate administration of intravenous or intramuscular hydrocortisone, followed by rapid fluid resuscitation using isotonic saline. It is a critical protocol for patients with adrenal insufficiency facing acute stressors such as infection, trauma, or surgery. Timely intervention prevents shock, organ failure, and death. Continued hydrocortisone dosing and endocrinologist oversight are essential until full clinical recovery is achieved.

According to the National Institutes of Health (NIH), adrenal insufficiency, the primary risk factor for adrenal crisis, has a prevalence of approximately 110-144 cases per million population.

Market Dynamics:

Driver:

Rising prevalence of autoimmune disorders

The escalating incidence of autoimmune conditions such as Addison's disease, congenital adrenal hyperplasia, and primary adrenal insufficiency significantly drives the adrenal crisis management market expansion. Improved diagnostic capabilities and enhanced awareness among healthcare professionals contribute to earlier detection rates. The growing geriatric population, particularly susceptible to endocrine disorders, further amplifies market demand. Moreover, lifestyle factors, including chronic stress, environmental toxins, and dietary changes, have been linked to increased autoimmune disorder prevalence. This epidemiological trend necessitates robust therapeutic interventions and emergency management protocols, thereby creating substantial market opportunities for pharmaceutical companies and medical device manufacturers specializing in adrenal crisis prevention and treatment solutions.

Restraint:

High cost of treatment

Emergency hydrocortisone injections, continuous hormone replacement therapy, and specialized monitoring equipment require considerable healthcare expenditure. The chronic nature of adrenal insufficiency demands lifelong treatment regimens, creating cumulative cost pressures for patients and healthcare systems. Moreover, limited insurance coverage for certain therapeutic options and diagnostic procedures exacerbates affordability challenges. The economic strain is particularly pronounced in developing regions where healthcare infrastructure and reimbursement policies remain inadequate, potentially limiting market penetration and adoption of advanced adrenal crisis management solutions across diverse patient populations.

Opportunity:

Digital health solutions for patient monitoring and adherence

Wearable devices equipped with cortisol monitoring capabilities enable real-time physiological tracking, facilitating proactive crisis prevention. Smartphone applications provide medication reminders, stress level monitoring, and emergency response protocols, improving patient outcomes. Telemedicine platforms connect patients with endocrinologists for remote consultations and dosage adjustments. Moreover, artificial intelligence algorithms can predict crisis episodes based on patient data patterns, enabling preventive interventions. The COVID-19 pandemic has accelerated digital health adoption, creating favorable market conditions for innovative monitoring solutions that enhance patient safety while reducing healthcare costs and hospital readmissions.

Threat:

Reimbursement hurdles for newer products and kits

Regulatory agencies require extensive clinical evidence demonstrating cost-effectiveness and safety profiles before approving coverage. Insurance providers often prioritize established treatments over innovative solutions, limiting access to advanced therapeutic options. The lengthy reimbursement approval timeline delays product commercialization and market entry strategies. Moreover, varying reimbursement policies across different regions and healthcare systems complicate global market penetration efforts. These challenges particularly affect emergency injection devices and novel diagnostic kits, potentially hindering innovation adoption and restricting patient access to cutting-edge adrenal crisis management technologies despite their clinical benefits.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the adrenal crisis management market through disrupted healthcare services and delayed routine monitoring appointments. Patients with adrenal insufficiency faced increased infection vulnerability, necessitating enhanced precautionary measures and stress-dose steroid protocols. Additionally, supply chain disruptions affected medication availability, particularly hydrocortisone products. Telemedicine adoption surged as healthcare providers sought alternative consultation methods, accelerating digital health solution integration. Moreover, the pandemic highlighted the importance of emergency preparedness, driving demand for home-based monitoring devices and self-administration kits for crisis management.

The glucocorticoid therapy segment is expected to be the largest during the forecast period

The glucocorticoid therapy segment is expected to account for the largest market share during the forecast period due to its fundamental role as the primary treatment modality for adrenal insufficiency and crisis prevention. Hydrocortisone remains the gold standard for hormone replacement therapy, with extensive clinical evidence supporting its efficacy and safety profile. Additionally, the segment encompasses various formulations, including oral tablets, injectable solutions, and emergency auto-injectors, catering to diverse patient needs. The well-established treatment protocols and physician familiarity with glucocorticoid administration contribute to sustained market leadership.

The paediatrics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pediatrics segment is predicted to witness the highest growth rate due to increasing recognition and diagnosis of congenital adrenal disorders in children. Early-onset conditions such as congenital adrenal hyperplasia and primary adrenal insufficiency require specialized treatment approaches tailored to pediatric physiology. Additionally, improved neonatal screening programs enable earlier detection, driving demand for age-appropriate therapeutic formulations and monitoring devices. The segment benefits from enhanced awareness among pediatric endocrinologists and primary care physicians regarding adrenal crisis recognition. Moreover, growing parental awareness and advocacy for comprehensive pediatric adrenal care further accelerates segment expansion.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share through advanced healthcare infrastructure, comprehensive insurance coverage, and robust pharmaceutical research capabilities. The region benefits from established endocrinology treatment centers and specialized adrenal insufficiency clinics providing expert patient care. Additionally, strong regulatory frameworks ensure product quality and safety while facilitating innovation adoption. High healthcare expenditure and patient awareness levels support premium treatment options and advanced monitoring technologies. Government initiatives promoting rare disease research and patient advocacy organizations contribute to sustained market growth.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by expanding healthcare infrastructure, increasing diagnostic capabilities, and rising disease awareness among healthcare professionals. Growing economic prosperity enables enhanced healthcare spending and access to advanced therapeutic options. Additionally, government initiatives promoting healthcare accessibility and insurance coverage expansion facilitate market penetration. The region benefits from a large patient population and improving epidemiological surveillance systems for endocrine disorders. Rising physician training programs in endocrinology and emergency medicine enhance crisis recognition and management capabilities. The digital health technology adoption and telemedicine integration further support rapid market expansion across diverse Asia Pacific healthcare systems.

Key players in the market

Some of the key players in Adrenal Crisis Management Market include Eton Pharmaceuticals, Takeda, Pfizer, Antares Pharma, Sandoz, Halozyme, Novartis, Teva, GSK, AbbVie, Mylan, Ferring, Hikma, Sun Pharma, Cipla, Sanofi, Bayer, AstraZeneca, Amneal, and Endo International.

Key Developments:

In July 2025, Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has launched Morphine Sulfate Injection, USP, in 2mg/mL and 4mg/mL doses in the US. The product has been launched in a prefilled syringe form and is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

In January 2022, Antares Pharma, Inc. a specialty pharmaceutical company, today announced positive results from a Phase I study for ATRS-1902 for adrenal crisis. The positive results support the advancement of the ATRS-1902 development program to a pivotal clinical study for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using our Vai™ novel proprietary rescue pen platform to deliver a liquid stable formulation of hydrocortisone.

In June 2021, Eton Pharmaceuticals, Inc the U.S. marketer of ALKINDI SPRINKLE®, a treatment for adrenocortical insufficiency in pediatric patients, today announced that it has acquired U.S. and Canadian rights to Crossject’s ZENEO® hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis.

Treatment Types Covered:
• Glucocorticoid Therapy
• Mineralocorticoid Therapy (Fludrocortisone)
• Fluid & Electrolyte Replacement Therapy
• Adjunctive Therapies

Route of Administrations:
• Intravenous (IV)
• Intramuscular (IM)
• Oral
• Subcutaneous

Patient Groups Covered:
• Adults
• Pediatrics
• Geriatrics
• Neonates

Distribution Channels Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Drug Distributors

End Users Covered:
• Hospitals
• Emergency Care Centers
• Specialty Clinics
• Home Care Settings
• Ambulatory Surgical Centers
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

• Company Profiling
Comprehensive profiling of additional market players (up to 3)
SWOT Analysis of key players (up to 3)
• Regional Segmentation
Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

200 Pages
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Adrenal Crisis Management Market, By Treatment Type
5.1 Introduction
5.2 Glucocorticoid Therapy
5.2.1 Hydrocortisone (IV/IM)
5.2.2 Dexamethasone
5.2.3 Other Glucocorticoids
5.3 Mineralocorticoid Therapy (Fludrocortisone)
5.4 Fluid & Electrolyte Replacement Therapy
5.5 Adjunctive Therapies
6 Global Adrenal Crisis Management Market, By Route of Administration
6.1 Introduction
6.2 Intravenous (IV)
6.3 Intramuscular (IM)
6.4 Oral
6.5 Subcutaneous
7 Global Adrenal Crisis Management Market, By Patient Group
7.1 Introduction
7.2 Adults
7.3 Pediatrics
7.4 Geriatrics
7.5 Neonates
8 Global Adrenal Crisis Management Market, By Distribution Channel
8.1 Introduction
8.2 Hospital Pharmacies
8.3 Retail Pharmacies
8.4 Online Pharmacies
8.5 Specialty Drug Distributors
9 Global Adrenal Crisis Management Market, By End User
9.1 Introduction
9.2 Hospitals
9.3 Emergency Care Centers
9.4 Specialty Clinics
9.5 Home Care Settings
9.6 Ambulatory Surgical Centers
9.7 Other End Users
10 Global Adrenal Crisis Management Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Eton Pharmaceuticals
12.2 Takeda Pharmaceutical Company Limited
12.3 Pfizer Inc.
12.4 Antares Pharma
12.5 Sandoz International GmbH
12.6 Halozyme Therapeutics
12.7 Novartis AG
12.8 Teva Pharmaceutical Industries Ltd.
12.9 GlaxoSmithKline plc
12.10 AbbVie Inc.
12.11 Mylan N.V.
12.12 Ferring Pharmaceuticals
12.13 Hikma Pharmaceuticals
12.14 Sun Pharmaceutical Industries Ltd.
12.15 Cipla Ltd.
12.16 Sanofi S.A.
12.17 Bayer AG
12.18 AstraZeneca plc
12.19 Amneal Pharmaceuticals
12.20 Endo International plc
List of Tables
Table 1 Global Adrenal Crisis Management Market Outlook, By Region (2024-2032) ($MN)
Table 2 Global Adrenal Crisis Management Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 3 Global Adrenal Crisis Management Market Outlook, By Glucocorticoid Therapy (2024-2032) ($MN)
Table 4 Global Adrenal Crisis Management Market Outlook, By Hydrocortisone (IV/IM) (2024-2032) ($MN)
Table 5 Global Adrenal Crisis Management Market Outlook, By Dexamethasone (2024-2032) ($MN)
Table 6 Global Adrenal Crisis Management Market Outlook, By Other Glucocorticoids (2024-2032) ($MN)
Table 7 Global Adrenal Crisis Management Market Outlook, By Mineralocorticoid Therapy (Fludrocortisone) (2024-2032) ($MN)
Table 8 Global Adrenal Crisis Management Market Outlook, By Fluid & Electrolyte Replacement Therapy (2024-2032) ($MN)
Table 9 Global Adrenal Crisis Management Market Outlook, By Adjunctive Therapies (2024-2032) ($MN)
Table 10 Global Adrenal Crisis Management Market Outlook, By Route of Administration (2024-2032) ($MN)
Table 11 Global Adrenal Crisis Management Market Outlook, By Intravenous (IV) (2024-2032) ($MN)
Table 12 Global Adrenal Crisis Management Market Outlook, By Intramuscular (IM) (2024-2032) ($MN)
Table 13 Global Adrenal Crisis Management Market Outlook, By Oral (2024-2032) ($MN)
Table 14 Global Adrenal Crisis Management Market Outlook, By Subcutaneous (2024-2032) ($MN)
Table 15 Global Adrenal Crisis Management Market Outlook, By Patient Group (2024-2032) ($MN)
Table 16 Global Adrenal Crisis Management Market Outlook, By Adults (2024-2032) ($MN)
Table 17 Global Adrenal Crisis Management Market Outlook, By Pediatrics (2024-2032) ($MN)
Table 18 Global Adrenal Crisis Management Market Outlook, By Geriatrics (2024-2032) ($MN)
Table 19 Global Adrenal Crisis Management Market Outlook, By Neonates (2024-2032) ($MN)
Table 20 Global Adrenal Crisis Management Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 21 Global Adrenal Crisis Management Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 22 Global Adrenal Crisis Management Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 23 Global Adrenal Crisis Management Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 24 Global Adrenal Crisis Management Market Outlook, By Specialty Drug Distributors (2024-2032) ($MN)
Table 25 Global Adrenal Crisis Management Market Outlook, By End User (2024-2032) ($MN)
Table 26 Global Adrenal Crisis Management Market Outlook, By Hospitals (2024-2032) ($MN)
Table 27 Global Adrenal Crisis Management Market Outlook, By Emergency Care Centers (2024-2032) ($MN)
Table 28 Global Adrenal Crisis Management Market Outlook, By Specialty Clinics (2024-2032) ($MN)
Table 29 Global Adrenal Crisis Management Market Outlook, By Home Care Settings (2024-2032) ($MN)
Table 30 Global Adrenal Crisis Management Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
Table 31 Global Adrenal Crisis Management Market Outlook, By Other End Users (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us